Hemostats Market

The report "Hemostats Market by Type (Thrombin, Combination, Gelatin, Collagen), Formulation (Matrix & Gel, Sheet & Pad, Sponge, Powder), Application (Orthopedic, General, Cardiovascular), End User (Hospital, Specialty Clinic), Region—Global Forecast to 2030", is projected to reach 4.00 billion in 2030 from USD 2.90 billion in 2025, at a CAGR of 6.4% during the forecast period.

Browse 230 market data Tables and 60 Figures spread through 261 Pages and in-depth TOC on "Hemostats Market - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/hemostats-market-9571619.html

The rapid proliferation of surgical centers and hospitals is expected to significantly bolster the hemostats market, as these facilities represent key end users of hemostatic agents. The expansion of healthcare infrastructure in both developed and emerging economies is contributing to this trend. The demand for surgical equipment, particularly hemostats, is robust in these newly established institutions, driven by an increasing patient population and a subsequent rise in surgical procedures. Moreover, the escalation of trauma incidents and the frequency of emergency surgeries has heightened the necessity for prompt and effective hemostatic measures within care facilities. This urgency is compounded by a growing emphasis on improving surgical outcomes and reducing intraoperative hemorrhage. As a result, healthcare providers are increasingly integrating reliable hemostatic agents into standard surgical protocols to enhance patient safety and outcomes.

In 2024, the oxidized regenerated cellulose-based hemostats segment held the largest market share, by type.

The hemostats market is segmented into oxidized regenerated cellulose-based hemostats, thrombin-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats based on type. The oxidized regenerated cellulose-based hemostats segment accounted for the largest share of the hemostats market in 2024. ORC-based hemostatic agents have emerged as the preferred choice for surgical hemostasis due to their proven efficacy across a range of surgical specialties, including orthopedics, cardiovascular, and general surgery. These hemostats consistently demonstrate reliable hemostatic performance, making them indispensable in various intraoperative settings. Their versatility across diverse operating room conditions ensures that they are often the clinician's first choice for managing complex clinical scenarios. One of the substantial advantages of ORC-based hemostats is their bioabsorbable composition, which eliminates the need for surgical removal post-procedure and minimizes the risk of foreign-body reactions. Furthermore, certain ORC formulations possess inherent antimicrobial properties, providing an added defense against surgical site infections and thereby enhancing patient safety and post-operative outcomes. The increasing incidence of trauma cases and emergency surgeries has intensified the demand for prompt and effective hemostatic interventions within healthcare systems. In light of this trend, institutions are compelled to integrate reliable hemostatic agents into standard surgical protocols, driven by the dual objectives of improving surgical outcomes and reducing intraoperative blood loss.

By 2024, the matrix & gel hemostats segment held the largest market share, by formulation.

The global hemostats market is differentiated into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. In 2024, the matrix & gel hemostats segment dominated the hemostats market. These formulations effectively balance versatility and efficacy, making them suitable for a wide range of surgical applications. Matrix and gel hemostats are particularly advantageous due to their straightforward application, even in challenging anatomical locations. Their ability to conform to irregular wound morphologies allows them to effectively address both profuse and oozing bleeding scenarios. Many formulations are compatible with laparoscopic techniques, facilitating the advancement of minimally invasive surgery. Moreover, certain matrix and gel combinations are integrated with active agents such as thrombin, which significantly enhances hemostatic performance and expedites clot formation.

Based on applications, the reconstructive surgery segment is expected to witness the highest CAGR during the forecast period.

The hemostats market has been segmented into orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, gynecological surgery, reconstructive surgery, and other surgical applications, based on application. The reconstructive surgery segment is expected to witness the highest CAGR during the forecast period in the hemostats market. The observed increase in surgical interventions can be attributed to the rising prevalence of aesthetic and trauma-related procedures, including skin grafting, breast reconstruction, and craniofacial surgeries. The growing recognition and acceptance of aesthetic treatments, alongside improved access to surgical options, are further driving this demand. Additionally, the rising incidence of cancer-related surgeries, particularly post-mastectomy reconstructions, as well as trauma cases, are significant contributors to market growth. These procedures often involve delicate tissues with high vascularity, where meticulous hemostatic control is essential. This underscores the critical need for effective hemostatic agents in the operating room. Furthermore, advancements in reconstructive technologies are accelerating the adoption of specialized hemostatic products, enhancing outcomes in this evolving sector.

By end user, the hospitals segment is expected to account for the largest share of the hemostats market during the forecast period.

The hemostats market can be divided by end user into three main categories: Hospitals, specialty clinics, and other end users. Hospitals represent the most substantial segment of the hemostats market, primarily due to the high volume of surgical procedures performed within their facilities. The intricate nature of these surgeries, along with the presence of specialized surgical departments, contributes significantly to the growing demand for effective bleeding control solutions. Complex and emergency cases, which frequently arise in hospitals, necessitate a reliable means of managing blood loss, thereby creating a continuous need for advanced hemostatic products. Additionally, hospitals often serve as the pioneers in adopting new surgical technologies and innovative products. This proactive approach is made possible by their enhanced funding capabilities and well-developed procurement processes, allowing them to stay at the forefront of medical advancements. The presence of highly skilled surgical specialists and comprehensive post-operative care units further amplifies the need for efficient hemostatic agents. These factors collectively ensure that hospitals remain a critical driver of demand in the hemostats market as they seek to improve patient outcomes and enhance surgical efficacy through cutting-edge bleeding control solutions.

North America was the largest regional hemostats market in 2024.

The market for hemostats has been divided into five key geographical regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America held the predominant portion of the hemostats market. North America is at the forefront of the hemostats market, propelled by its advanced healthcare infrastructure and the swift integration of cutting-edge medical technologies. This region exhibits a robust demand for both cosmetic and restorative procedures, significantly influenced by the escalating geriatric demographic and an uptick in surgical interventions. The increasing incidence of chronic diseases is projected to further amplify the volume of surgical procedures, thereby enhancing the requirement for effective hemostatic agents. The region’s leadership in both innovation and market share is underscored by the concentration of numerous key players in the hemostats industry. Additionally, the high levels of disposable income and elevated standard of living in nations such as the US and Canada significantly contribute to the growing demand for premium medical treatments.

The prominent players in the hemostats market include Johnson & Johnson Services, Inc. (US), Baxter (US), Pfizer Inc. (US), B. Braun SE (Germany), BD (US), Teleflex Incorporated (US), Medtronic (Ireland), Hemostasis, LLC (US), Stryker ((US), Integra LifeSciences Corporation (US), Advanced Medical Solutions Group plc (UK), Samyang Corporation (South Korea), Marine Polymer Technologies, Inc. (US), GELITA MEDICAL (Germany), Dilon Technologies (US), Betatech Medical (Turkey), Meril Life Sciences Pvt. Ltd. (India), BioCer Development GmbH (Germany), Unilene (Peru), Katsan Medical Devices (Turkey), Tricol Biomedical (US), 3-D Matrix Medical Technology (Japan), Hemostat Medical GmbH (Germany), CELOX Medical Ltd. (UK), and Altaylar Medical (Turkey). Among other developments, these companies adopted strategies such as partnerships, collaborations, agreements, integrations, acquisitions, product launches, and expansions to strengthen their presence in the hemostats market.

Don’t miss out on business opportunities in Hemostats Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/